Hotline – Election Day Closure

ATTENTION: HealthWell Foundation’s hotline will be closed on Tuesday, November 3, 2020 to allow our contact center team the flexibility to safely vote. The hotline will re-open on Wednesday, November 4, 2020 at 9:00 a.m. We encourage you to continue to use our Patient, Pharmacy and Provider Portals during this time.  Please note: if you are contacting us about a payment or grant, it is faster to email us at grants@healthwellfoundation.org.  The HealthWell Team.

 

 

Dismiss alert
By Claire Saxton, Vice President, Education and Outreach, Cancer Support Community  |  Sep 2, 2020

CAR-T Cell Immunotherapy: What to Expect

As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC), including its Gilda’s Club affiliates, is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community. CSC achieves its mission through three areas: direct…more.

By Lee Greenberger, PhD, Chief Scientific Officer, The Leukemia & Lymphoma Society  |  Aug 19, 2020

The Evolution of CAR-T Therapy

Over the past two decades there’s been tremendous progress in understanding how to harness the body’s immune system to fight cancer. Today, immunotherapy is a mainstay of cancer treatment. One of the most exciting areas of immunotherapy is CAR (chimeric antigen receptor) T-cell therapy. This treatment involves purifying a special…more.

By Real World Health Care Editorial Staff  |  Aug 5, 2020

Multiple Myeloma Research Foundation: CAR-T Cell Therapy Initiatives

Last year, the Multiple Myeloma Research Foundation (MMRF) launched a new, three-year strategic plan to help transform how multiple myeloma is treated and ultimately cured. One of the plan’s three strategic pillars focuses on immunotherapy, including chimeric antigen receptor T-cell (CAR-T) therapy. Real World Health Care spoke with the MMRF’s…more.

By Emily Burke, Ph.D., Director of Instruction, BiotechPrimer.com  |  Mar 11, 2020

Search & Destroy: Chimeric Antigen Receptor T-Cells (CAR-T)

Editor’s Note: The following article is reprinted, with permission from Biotech Primer. The original version appeared in the Biotech Primer WEEKLY. To subscribe to the Biotech Primer WEEKLY, click here. The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—tisagenlecleucel and axicabtagene ciloleucel were approved in 2017, and…more.

By Gareth J. Morgan, MD, FRCP, FRCPath, PhD, Professor of Hematology & Director of the Myeloma Institute, University of Arkansas for Medical Sciences  |  Nov 29, 2017

Multiple Myeloma: A Rare and Complex Cancer

We continue our series on multiple myeloma with an interview with Gareth J. Morgan, MD, FRCP, FRCPath, PhD, professor of hematology and director of the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS). Dr. Morgan also serves as deputy director of the Winthrop P. Rockefeller Cancer Institute…more.

Categories: General, Multiple Myeloma
By Shaji Kumar, MD, Professor of Medicine, Hematology, Mayo Clinic  |  Nov 1, 2017

Multiple Myeloma: Promising New Therapies, But Challenges Remain

This week, our series on multiple myeloma continues as we talk about immunotherapies and other promising new treatments with Shaji Kumar, MD. Dr. Kumar is a professor of medicine in the division of hematology at Mayo Clinic, where he chairs the myeloma group across all three Mayo sites. Dr. Kumar…more.

Categories: General, Multiple Myeloma
By Real World Health Care Editorial Staff  |  Jul 26, 2017

Advancing Melanoma Research & Supporting Patients

Our series on melanoma concludes as we shine the spotlight on the Melanoma Research Foundation (MRF). We spoke with the MRF’s Director of Education, Shelby Moneer, MS, CHES and MRF’s Scientific Advisory Committee Co-Chair, Michael B. Atkins, MD, PhD, Deputy Director of the Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University. The…more.

Categories: General, Melanoma
By Real World Health Care Editorial Staff  |  Jul 11, 2017

Cutting-Edge Melanoma Treatment at Rutgers Cancer Institute of New Jersey

This week, Real World Health Care continues our series on melanoma by interviewing two colleagues from the Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center. Sharad Goyal, MD, is Associate Professor and Director of Clinical and Translational Research in the department of Radiation Oncology. He…more.

By Kelly M. McMasters, MD, PhD, James Graham Brown Cancer Center, University of Louisville  |  Jun 28, 2017

Fighting Melanoma with Immunotherapy

For this week’s post in our series on melanoma melanoma, Real World Health Care interviewed Kelly M. McMasters, MD, PhD. Dr. McMasters serves as the director of the Multidisciplinary Melanoma Clinic at the University of Louisville’s James Graham Brown Cancer Center. Here, he works with colleagues to identify the most…more.

By Howard Kaufman, MD, FACS, Rutgers Cancer Institute of New Jersey  |  Jun 14, 2017

Harnessing the Immune System to Treat Melanoma

Real World Health Care continues our series on melanoma with a discussion with Howard Kaufman, MD, FACS, surgical oncologist at Rutgers Cancer Institute of New Jersey. Dr. Kaufman’s clinical and research work focuses on using the immune system to fight cancer. He also runs a scientific laboratory focusing on oncolytic…more.

Close menu